Evgen Pharma Share Discussion Threads

[hodhasharon] 11/3/2021 07:18

We might not be going to the moon just yet....but we're certainly preparing the rocket!

[moneymunch] 11/3/2021 07:13

Lol....yep, of course it is.....even better, i was mixing up my H & Q's...;-)

[2seabass] 11/3/2021 07:12

Q2 is April to end June

[awise355] 11/3/2021 07:08

Just seen that thanks!

[moneymunch] 11/3/2021 07:07

Yep, but the all important interim efficacy data will be available during Q2 2021, ie any time from July. Gl ;-)

[moneymunch] 11/3/2021 07:04

Exciting times!!! Gla HOLDERS!!!! ;-)))

[awise355] 11/3/2021 07:03

End of 2021? Expected I missed that

[moneymunch] 11/3/2021 07:03

RNS Number : 8634R
Evgen Pharma PLC
11 March 2021


Evgen Pharma plc

("Evgen" or the "Company")



Update on Data Safety Review for STAR COVID-19 trial

Review of Patient Safety and Data Quality confirms no concerns with trial



Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces that after a review of the first 60 patients enrolled, the Data Safety Monitoring Committee ("DMC") for the STAR COVID-19 ("SFX-01 Treatment for Acute Respiratory infections") trial has concluded that there are no concerns regarding patient safety or data quality that would prevent continuation of the trial.



The Phase II/III trial is a double blind, randomised, placebo-controlled study of the Company's lead asset, SFX-01, in patients with acute respiratory distress syndrome (''ARDS''). The trial is co-sponsored by the University of Dundee and NHS Tayside and funded by the UK charity LifeArc. It is investigating whether the Company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with suspected COVID-19. Patients may be included in the study if they are infected with SARS-CoV-2 or other respiratory infections causing community-acquired pneumonia.



Following this positive step, the next event in the trial involves an assessment of safety and futility by the DMC of unblinded data on the first 100 patients treated. In addition to the DMC safety and futility assessment, Dundee University has decided to review the top-level unblinded data in a preliminary assessment of possible efficacy. This may lead to adjustments to the design of the trial for remaining patients, including in-patient numbers, and possibly early termination for either safety, futility or alternatively, strong efficacy. It is expected that this initial data will be available during Q2 of the calendar year 2021.



Completion of recruitment to the STAR trial is anticipated at the end of 2021/early 2022, assuming there are no substantial changes in the total patients to be recruited.



Dr Huw Jones, CEO of Evgen, commented: "We are pleased with the conclusion of the data monitoring committee with regard to safety and data quality in the STAR COVID 19 study. The former conclusion reinforces what we know about the positive safety and tolerability of SFX-01 from previous studies and the latter is yet another testament to the excellent work carried out by Professor James Chalmers and his colleagues at Dundee under challenging circumstances."

[moneymunch] 11/3/2021 06:56

Huw bought 65k shares, yet he already had 2.9m share options.....Sue Foden bought 125k shares as well as share options in place, not every Director is cash rich as you think they are, and if i had 2.9m share options in Evgen, i personally would be investing my money elsewhere to spread the investment risk, there are no guarantees in this game but there lies the transformational upside opportunity on Evgen's prospects and potential, multiple shots on multiple targets and attracting the substantial investment from Octopus the UK's leading VC fund, and more disclosures to come. Share options in place can only be exercised after achieving significant share price value, and so a win win win for all concerned with Huw and the BoD incetivised to deliver growth and shareholder value. Gla Holders....this will move BIG time as the placing dust settles and Huw updates the market on progress made.....and fully funded until mid 2023 at 8p a share...Fill Ya Boots!!!!! ;-)

[nico115] 10/3/2021 23:02

Tell me why directors won't buy then mm ?You've been bullish on this share for years yet we are near all time Lows If directors aren't confident ,why are you ?

[moneymunch] 10/3/2021 22:39

Lol...Octopus, the market leading VC bought 7.9% of the company, so stop worrying, they're obviously much more confident in Evgen's prospects and potential than you....I reckon it might be best to sell your 2m and move on mate. Gl :-)

[nico115] 10/3/2021 22:12

Options don't count They cost nothing One director bought 3k shares,250 pounds Wow wow wow What drug failed last year ? We have one more shot and that's it imho I'm bullish but the lack of director buying is a major worry for me and I'm close to selling out

[moneymunch] 10/3/2021 21:26

Anyways, 2 Directors bought shares, Sue Foden had 125k and Huw had 62k, there's also 7m plus share options held by the BoD including 2.9m awarded to Huw on his appointment as CEO, and so plenty of skin in the game and plenty of incentives to deliver shareholder value...multiple shots on multiple targets and fully funded until mid 2023, so the chances for success here are better than most imho... Gla :-)

Details of the Directors Buys:

[moneymunch] 10/3/2021 19:49

Recent research that adds weight to SFX-01's chances of success for Covid/Ards...Gla :-)

Covid-19 Abstracts 

Divulging the Intricacies of Crosstalk Between NF-Kb and Nrf2-Keap1 Pathway in Neurological Complications of COVID-19

 March 8, 2021

.......

Perspectives and Conclusion

COVID-19 received the status of a pandemic on March 11, 2020, by WHO. Since its first case in Wuhan, China in December 2019, the disease has come a long way, with the number of cases and the number of deaths surging daily. Oxidative stress and inflammatory cytokine storm are key characteristics of the pathology concerning this deadly virus. Many studies discussed point the substantial body of evidence hinting at severe neurological complications in patients.

Various drugs have been repurposed to cater to the emergent need for therapeutics. The development and early approval of vaccines have been fast-tracked all around the globe. While the citizens of the globe await an efficacious vaccine, there is a dire need for innovative therapeutic approaches to cater to this deadly disorder. Crosstalk between both, NF-κB and Nrf2 signaling pathway lies at the center of neurological complications in COVID-19 patients. Immuno-modulators both synthetic and natural can be promising candidates in catering to the pathologies targeted in the aforementioned pathways.

Immunomodulatory agents act in synergism with the pre-existing approaches and act as adjunctive therapy or prophylaxis and outstand existing approaches by specifically targeting the oxidative stress and consequently, eradicating and undermining the pathology leading to severe neurological disorders.

[bumpa33] 10/3/2021 19:41

Firstly, if you knew anything about Griffiths you’d know that him selling is a pretty ambiguous signal.


Secondly - the raise wasn’t three times the original size, but even if it was - how do you know it wasn’t the investors pressing to give them more than their original ask? It happens and is a bullish sign.


Thirdly - I’ll give you the lack of director buying, though it’s not such an important thing as far I’m concerned as it once was. It rather depends on other contributing factors as to whether it’s a negative or a meh.

[nico115] 10/3/2021 19:33

Apologise first amaretto

[amaretto1] 10/3/2021 19:17

When did you buy them ?

[nico115] 10/3/2021 19:04

Hope so and I'm not bearish My main worry is directors have no skin in the game

[nico115] 10/3/2021 19:03

I bought 600k STX at 30p and love them more than evg cos no director buying here

[moneymunch] 10/3/2021 18:22

"They were trying to raise a lot less"??? but ended up with £11m...very well done Huw, c£13m cash in the bank and so fully funded until mid 2023 to accelerate development of their multiple disease target pipeline, and so a raft of potential positive newsflow from Huw in the coming weeks that could add significant value....all looks good to me nico and not surprised you're holding, stunning prospects and potential for Transformational upside. Gl :-)

[amaretto1] 10/3/2021 17:12

I'm sick of listening to his stupid questions here and on STX I'll say no more.

[nico115] 10/3/2021 16:58

My understanding is they were initiallytrying to raise a lot less They did wellBut why raise so much ?